Supernus Pharmaceuticals (SUPN) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD.
The updated label describes the drug's "partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter," which highlights the treatment's "multimodal pharmacodynamic profile," the biopharmaceutical company said.
The revised label also includes new lactation data for breastfeeding women with ADHD "showing that the transfer of Qelbree into breastmilk is low," Supernus said.
The drug is approved for use by people ages 6 years and older with ADHD, the company said.
SUPN shares were up 1.8% in early trading.
Price: 38.85, Change: +0.30, Percent Change: +0.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。